Scott R. Solomon, MD, discusses the rationale for examining lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
Scott R. Solomon, MD
Advertisement
Articles by Scott R. Solomon, MD
Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
4
Dr Neff on the Accuracy and Feasibility of Self-Collected HPV Testing in Cervical Cancer
5